Get the Stockscreener App
37.27
0.69%
0.255
After Hours:
37.27
Revolution Medicines Inc stock is traded at $37.27, with a volume of 1.32M.
It is up +0.69% in the last 24 hours and up +1.30% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$37.02
Open:
$36.84
24h Volume:
1.32M
Relative Volume:
0.60
Market Cap:
$6.94B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-10.18
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
+0.13%
1M Performance:
+1.30%
6M Performance:
-13.22%
1Y Performance:
-18.34%
1-Day Range:
$36.77
$38.10
1-Week Range:
$36.60
$38.45
52-Week Range:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
37.27 | 6.89B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
What is the dividend policy of Revolution Medicines Inc. Equity Warrant stockTop Growth Tips For Consistent Profits - jammulinksnews.com
What is the risk reward ratio of investing in Revolution Medicines Inc. Equity Warrant stockBest Dividend Tracker For Every Investor - jammulinksnews.com
When is Revolution Medicines Inc. Equity Warrant stock expected to show significant growth - jammulinksnews.com
Published on: 2025-07-31 08:16:00 - beatles.ru
Can volume confirm reversal in Revolution Medicines Inc.Short Term Trading Opportunity Watch Sees Shift - metal.it
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - GlobeNewswire
Moving Average Crossover Confirms Uptrend in Revolution Medicines Inc.Triple Digit Return Stock Predictions Released - metal.it
Why Revolution Medicines Inc. Equity Warrant stock attracts strong analyst attentionCarefully Curated High Return Stocks - beatles.ru
Published on: 2025-07-29 11:05:23 - metal.it
Revolution Medicines Inc. Hits Price Floor — Bounce IncomingEntry Points For Growing Stocks Identified by Models - metal.it
Published on: 2025-07-29 03:06:19 - metal.it
MACD Cross Could Confirm Trend in Revolution Medicines Inc. Equity WarrantDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
What are the latest earnings results for Revolution Medicines Inc. Equity WarrantFree Stock Watchlist For Fast Growth - jammulinksnews.com
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade - sharewise.com
What catalysts could drive Revolution Medicines Inc. Equity Warrant stock higher in 2025Unmatched market gains - jammulinksnews.com
When is Revolution Medicines Inc. stock expected to show significant growthPhenomenal capital gains - jammulinksnews.com
What is Revolution Medicines Inc. Equity Warrant company’s growth strategyFree Wealth Planning Blueprint - jammulinksnews.com
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Published on: 2025-07-28 12:03:58 - metal.it
Is it the right time to buy Revolution Medicines Inc. stockConsistent triple-digit returns - jammulinksnews.com
What is the risk reward ratio of investing in Revolution Medicines Inc. stockUnlock daily market insights for better trades - jammulinksnews.com
What institutional investors are buying Revolution Medicines Inc. Equity Warrant stockDaily Trading Tracker For Fast Growth - jammulinksnews.com
Is Revolution Medicines Inc. a growth stock or a value stockExponential return rates - jammulinksnews.com
How strong is Revolution Medicines Inc. company’s balance sheetCapitalize on emerging market trends - jammulinksnews.com
How does Revolution Medicines Inc. Equity Warrant generate profit in a changing economyPowerful growth strategies - jammulinksnews.com
Is Revolution Medicines Inc. stock overvalued or undervaluedInvest smarter with high-probability setups - jammulinksnews.com
How many analysts rate Revolution Medicines Inc. Equity Warrant as a “Buy”Triple returns potential - jammulinksnews.com
Published on: 2025-07-27 21:27:33 - jammulinksnews.com
How volatile is Revolution Medicines Inc. Equity Warrant stock compared to the marketUnlock expert stock analysis and alerts - jammulinksnews.com
Is Revolution Medicines Inc. Equity Warrant a growth stock or a value stockUnlock powerful portfolio optimization tools - jammulinksnews.com
What makes Revolution Medicines Inc. Equity Warrant stock price move sharplyFree Insider Trading Tips - metal.it
What analysts say about Revolution Medicines Inc. stockSuperior stock selection - PrintWeekIndia
Revolution Medicines, Iambic Therapeutics Partner to Use AI for Novel RAS-Addicted Cancer Drug Discovery - Insider Monkey
What drives Revolution Medicines Inc. Equity Warrant stock priceTriple returns potential - Autocar Professional
Is Revolution Medicines Inc. a good long term investmentTremendous growth opportunities - PrintWeekIndia
What analysts say about Revolution Medicines Inc. Equity Warrant stockFastest-growing stock picks - PrintWeekIndia
Revolution Medicines publishes research on RAS G12D inhibitor - Investing.com
Revolution Medicines publishes research on RAS G12D inhibitor By Investing.com - Investing.com South Africa
Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastHigh-octane financial growth - Autocar Professional
What drives Revolution Medicines Inc. stock priceBreakthrough stock performance - Autocar Professional
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewswire
RVMDRevolution Medicines, Inc. Latest Stock News & Market Updates - Stock Titan
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewswire
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):